Physician profile
Christopher Otero
NPI 1346928090
$6,389.57
in general payments reported to CMS, 2019-2025
26 companies · $4,718 in 2025
The $4,718 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,671 · 2025: $4,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,770 · Consulting Fee: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,769.57 |
| Consulting Fee | $1,620.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,614.46 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Astrazeneca Pharmaceuticals LP | $692.34 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $394.76 | 2024 | Reblozyl, Opdivo |
| Abbvie INC. | $244.60 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $223.88 | 2024-2025 | |
| Incyte Corporation | $171.51 | 2024-2025 | Monjuvi, Pemazyre |
| Emd Serono, INC. | $146.21 | 2025 | |
| Genentech USA, INC. | $143.47 | 2025 | |
| Dendreon Pharmaceuticals LLC | $135.43 | 2025 | Provenge |
| Novocure INC. | $130.56 | 2025 | Optune Lua (Novottf-200t) |
| Caris Mpi, INC. | $128.25 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $125.00 | 2024 | Elzonris |
| Sobi, INC | $124.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.90 | 2025 | Fruzaqla |
| Beone Medicines USA, INC. | $123.50 | 2025 | Brukinsa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $118.39 | 2025 | Xtandi |
| Amgen INC. | $114.38 | 2025 | Blincyto |
| Genentech, INC. | $112.52 | 2024 | |
| Pfizer INC. | $102.37 | 2024 | |
| Phathom Pharmaceuticals, INC. | $101.98 | 2024 | Voquezna |
| Avanos Medical | $100.96 | 2024 | On-Q* Pump and Accessories |
| Janssen Scientific Affairs, LLC | $87.60 | 2024 | Akeega, Balversa, Erleada |
| Rigel Pharmaceuticals, INC. | $57.36 | 2024 | Rezlidhia, Tavalisse |
| Novartis Pharmaceuticals Corporation | $31.25 | 2025 | |
| Immunocore Limited | $21.71 | 2025 | Kimmtrak |
| Sanofi-Aventis U.S. LLC | $17.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Otero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.